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ABSTRACT
Introduction Exercise is emerging as a therapy in
oncology for its physical and psychosocial benefits
and potential effects on chemotherapy tolerability and
efficacy. However, evidence from randomised controlled
trials (RCTs) supporting exercise in patients with
borderline resectable or locally advanced pancreatic
cancer (PanCa) undergoing neoadjuvant therapy (NAT) are
lacking.
Methods and analysis The EXPAN trial is a dual-centre,
two-armed, phase I RCT. Forty patients with borderline
resectable or locally advanced PanCa undergoing NAT
will be randomised equally to an exercise intervention
group (individualised exercise+standard NAT) or a
usual care control group (standard NAT). The exercise
intervention will be supervised and consist of moderate to
vigorous intensity resistance and aerobic-based training
undertaken two times a week for 45–60 min per session
for a maximum period of 6 months. The primary outcome
is feasibility. Secondary outcomes are patient-related
and treatment-related endpoints, objectively measured
physical function, body composition, psychological health
and quality of life. Assessments will be conducted at
baseline, prior to potential alteration of treatment (~4
months postbaseline), at completion of the intervention
(maximum 6 months postbaseline) and 3-month and
6-month postintervention (maximum 9 and 12 months
postbaseline).
Ethics and dissemination The EXPAN trial has been
approved by Edith Cowan University (reference no.: 202002011-LUO), Sir Charles Gairdner Hospital (reference
no.: RGS 03956) and St John of God Subiaco Hospital
(reference no.: 1726). The study results will be presented
at national/international conferences and submitted for
publications in peer-reviewed journals.
Trial registration number ACTRN12620001081909.
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INTRODUCTION
Advances in neoadjuvant therapy (NAT) and
surgical techniques for pancreatic cancer
(PanCa) have improved the likelihood of
patients with borderline resectable or locally
advanced disease undergoing curative-intent
surgery.1 2 However, rates of operability and
margin-negative (R0) resection remain low
for patients with borderline resectable (operability: 69%, R0: 54%) or locally advanced
(operability: 26%, R0: 23%) PanCa after
NAT (based on various pre-NAT resectability
criteria)3 due to poor response to current
regimens. This may be due to the complex
microenvironment of PanCa characterised
by a high percentage of tumour stroma that
leads to dysfunction in nearby blood vessels
and impedes drug delivery to tumour cells.4
In addition, dose reductions, dose delays and
reduced relative dose intensity (RDI) are
common in these patients during NAT due
to dose-
limiting toxicities (such as fatigue,
neutropenia, vomiting and diarrhoea),5 6
which can also contribute to reduced therapeutic response.7
Patient physical condition is an important
consideration before proceeding to PanCa
surgery.2 8 However, patients with PanCa
are relatively older (median age 71 years)2
and are at high risk of developing debilitating syndromes including sarcopaenia and
cachexia.9 These factors along with cumulative toxicities of NAT can worsen patients’
preoperative condition and, in turn, increase
1
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risk of complications and prolonged recovery after
surgical resection, ultimately impairing their long-term
survival.10 11 Further, side effects relating to PanCa and
its treatments have a negative impact on patients’ psychological health and quality of life (QoL).12 13 Given the
suboptimal responses to current NAT and the extensive
treatment-
related side effects in patients with borderline resectable or locally advanced PanCa, research into
interventions to address these unmet needs is of clinical
importance.
Exercise has been recommended as an effective therapy
for persons following a cancer diagnosis in managing
fatigue, psychological distress, muscle loss and declines
in physical function and QoL.14 15 Of importance, there
is early evidence suggesting that exercise may serve as
a potential strategy to improve chemotherapy tolerability.16 17 Further, preclinical and clinical trials (including
a trial in patients with PanCa) suggest that exercise
normalises tumour vasculature, which in turn may lead
to augmented efficacy of chemotherapy via increasing
drug delivery.18–21 Despite the benefits associated with
exercise in cancer management, only seven exercise trials
have been undertaken in patients with PanCa with over
half being case reports or a case series.22–24 Although a
recent systematic review by our team found that exercise may be safe and feasible in patients with PanCa,24
most of the patients enrolled in the studies were highly
selected having already successfully completed NAT and
surgical resection. Additionally, a case series25 and a case
report26 of patients with borderline resectable or locally
advanced PanCa during NAT performing supervised
exercise training showed promising results that warrant
further investigation with a more rigorous study design.
Therefore, we propose to undertake a pilot randomised
controlled trial (RCT) to examine the feasibility and
efficacy of a supervised, multicomponent exercise
programme in patients with borderline resectable or
locally advanced PanCa undergoing NAT.
METHODS AND ANALYSIS
In this manuscript, we describe the rationale and design
considerations of the EXPAN trial. The protocol was
developed and reported according to the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines.27
Study design
The study design and a schematic schedule for enrolment, intervention and assessments of the EXPAN trial
is outlined in figures 1 and 2, respectively. The EXPAN
trial is a dual-centre, two-armed, phase I RCT to examine
the feasibility and efficacy of a supervised, multicomponent exercise medicine programme in patients with
borderline resectable or locally advanced PanCa undergoing NAT. Following completion of eligibility screening,
informed consent and baseline assessment, recruited
patients will be randomised equally to an intervention
2

group (individualised exercise training concomitant
with standard NAT) or a usual care control group (standard NAT). Participants will undergo additional assessments at completion of the intervention (maximum 6
months postbaseline), 3-month and 6-month postintervention (maximum 9 and 12 months postbaseline). For
participants who will undergo additional chemotherapy
with or without radiation (including CyberKnife) after
induction chemotherapy, a midpoint assessment will be
performed before the alteration of treatment (~4 months
postbaseline).
Eligibility criteria
Men and women diagnosed with borderline resectable
or locally advanced pancreatic ductal adenocarcinoma as
per the Australasian Gastro-Intestinal Trials Group definition (AGITG)28 will be invited to participate in the study.
Major inclusion and exclusion criteria are as follows:
Inclusion criteria
1. Age ≥18 years.
2. Waiting to start or within 4 weeks after starting their
prescribed neoadjuvant chemotherapy with or without
locoregional radiotherapy.
3. Approved by their treating oncologist to participate in
the trial.
Exclusion criteria
1. Recurrent PanCa with or without exposure to previous
chemotherapy.
2. Having undergone treatments for another primary
cancer within the last 12 months, or another ongoing
active primary malignancy.
3. Anticipating undergoing major surgery for non-cancer
diseases within the next 6 months.
4. Any musculoskeletal, cardiovascular or neurological
disorder that could put them at risk during exercise
testing and training.
5. Having participated in planned, individualised and
supervised exercise training for ≥2 days/week in the
previous month.
6. Unable to travel to any designated training and/or
testing site.
Sample size
Given the pilot nature of the EXPAN trial investigating
primarily the safety and feasibility of the exercise intervention in patients with PanCa during NAT, no formal
sample size calculation was performed a priori. However,
according to the study clinicians, the number of participants that is viable over a 12-month recruitment period
in the participating hospitals would be approximately
40 (ie, 20 per group). This has been reported to be an
acceptable sample size for a pilot RCT (ie, 12–35 persons
per group).29–31
Recruitment
The EXPAN trial will receive support for recruitment from
the Multidisciplinary Team in Upper Gastrointestinal
Luo H, et al. BMJ Open Gastro 2021;8:e000642. doi:10.1136/bmjgast-2021-000642
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Figure 1 Flowchart of study design. *Only for participants who are unresectable and will undergo additional chemotherapy
with or without radiation (including CyberKnife) after induction chemotherapy. CTx, chemotherapy; Ex, exercise intervention;
NAT, neoadjuvant therapy; RTx, radiotherapy.

Cancers at Sir Charles Gairdner Hospital (SCGH) and
St John of God Subiaco Hospital (SJOGSH). Participants will be recruited using the following methods: (1)
The study investigator reviews electronic clinical notes
at SJOGSH every 2 weeks to initially identify potential
participants. Subsequently, the attending oncologist or
clinical nurse is asked for confirmation of their clinical
eligibility and permission to contact. (2) The attending
oncologists or clinical nurses at both hospitals identify
clinically eligible patients and inform them about the
study. Should patients express an interest in the study
and provide permission, their contact details will be
passed to the study investigator. On obtaining permission to contact potential participants in either way, the
investigator will approach them by telephone to discuss
all aspects involved with the study and perform eligibility
screening. Patients who meet the eligibility criteria and
are interested in the study will then be invited to participate and will be provided with a set of recruitment documents and questionnaires via post, email, fax or Microsoft
Forms (for questionnaires) as appropriate. They will be
Luo H, et al. BMJ Open Gastro 2021;8:e000642. doi:10.1136/bmjgast-2021-000642

advised to provide written informed consent before the
baseline assessment.
In addition, participants will be recruited through
advertisement posting on the website of the Exercise
Medicine Research Institute (EMRI) at Edith Cowan
University (ECU). Interested patients can contact the
study investigator via phone or email for further information regarding the EXPAN trial.
Randomisation and blinding
After completion of the baseline assessment, participants
will be randomly allocated on a 1:1 basis to an exercise
intervention group or a usual care control group using
a random allocation sequence generated by a secure
website, Sealed Envelope (London, UK).32 The randomisation will be stratified by participants’ disease stage
(borderline resectable vs locally advanced) and age (<65
years vs ≥65 years) to account for variations in historical
operability rate following standard NAT in the hospitals.
Random permuted blocks (block size 2 and 4) will be
employed to ensure balanced allocation of participants
3
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Figure 2 SPIRIT schematic schedule of enrolment, interventions and assessments for the EXPAN trial. ●: fixed assessment
time points; ○: potential assessment time point. *Only for the intervention group. †Measured in line with routine clinical
examination of the hospitals with the data collected closest to the predefined assessment time points (ie, Tm, T1 and T3)
used for the EXPAN trial. ‡Only for participants receiving pancreatic cancer surgery. BSI-18, Brief Symptom Inventory-18;
DXA, dual X-ray absorptiometry; EORTC QLQ, European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire; GSLTPAQ, The Godin-Shephard leisure-time physical activity questionnaire; 1 RM, 1-repetition maximum;
PACES, physical activity enjoyment scale; RADL, resumption of activities of daily living; RPE, the rating of perceived exertion
(the 10-point Borg Scale); T0, baseline; Tm, potential midpoint (~4 months postbaseline); T1, at completion of the exercise
intervention (maximum 6 months postbaseline); T2, 3 months after T1 (maximum 9 months postbaseline); T3, 6 months after T1
(maximum 12 months postbaseline).

into both groups. Assessors of the efficacy outcomes
and participants’ treating oncologists will be blinded to
group allocation. Due to the nature of the exercise intervention, participants will not be blinded to intervention
assignment following randomisation. However, they will
be required not to reveal their group allocation to the
assessors and their treating oncologists.
Intervention
An overview of the exercise intervention is provided in
table 1. The exercise program is scheduled for a maximum
period of 6 months, which will be terminated prior to
potential surgical resection. Participants in the intervention
group will undertake individually tailored exercise training
in any of the three ECU affiliated exercise clinics/facilities
that covers different areas of the city. They will be required
to exercise at a frequency of two sessions per week with
45–60 min/session (including a 5 min warm-up and cool-
down). In each session, participants will perform 20–30 min
of resistance training and a maximum 20 min of aerobic-
based exercise (continuous cycling or intermittent sport-
related activities). All the prescribed exercise components
in a session will be performed in a one-to-one fashion or in
a small group depending on participants' training schedule
or availability and closely supervised by the investigator. The
exercise programme will follow the principle of progressive overload and autoregulated based on a participant’s
4

perceived readiness for training at the start of an exercise
session. Given that participants will be exercising during
NAT, a flexible training schedule will be adopted to accommodate individual treatment schedule. In addition, participants who are absent from a session will be followed up via
phone and encouraged to make up for a missed session
anytime in the same week (ie, during daytime on weekdays
and weekends).
Resistance training
Resistance training will involve 4–6 exercises that cover the
major muscle groups of the upper-
body and lower-
body
using machines and dumbbells (such as overhead press, latissimus pull-down, chest press, seated row, leg press and leg
curl). For each exercise, participants will perform 1–3 sets
at 8–12 repetition maximum with 60 s recovery between sets.
The weight will be increased by 5%–10% when a participant
can successfully complete two additional repetitions on the
last set of an exercise for two consecutive sessions.33 A similar
resistance training regimen has been tested and shown to be
acceptable in patients following PanCa surgery.34
Aerobic-based exercises
In addition to resistance training, each session includes a
maximum of 20 min of either continuous cycle ergometer
exercise or intermittent sport-
related activities (such as
repeated punches thrown and agility ladder drills), which
Luo H, et al. BMJ Open Gastro 2021;8:e000642. doi:10.1136/bmjgast-2021-000642
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Table 1 Overview of the exercise programme
Length of exercise
program
Setting

Maximum 6 months
Edith Cowan University affiliated exercise clinics/facilities

Frequency

2 sessions per week

Session duration

45–60 min (including 5 min warm-up and cool-down)

Warm-up

Low-intensity aerobic exercise (eg, treadmill walking)

Cool-down

Static stretching

Resistance training
Exercises

Overhead press, latissimus pull-down, chest press, seated row, leg press and leg curl

Equipment

Weight machines and dumbbells

Duration

20–30 min/session

Number of sets

1–2 (weeks 1–4), 3 (weeks 5 onwards)

Number of repetitions

12 RM (weeks 1–8), 10 RM (weeks 9–16), 8 RM (weeks 17 onwards)

Recovery between sets 60 s
Progression

5%–10% weight increase following the 2-for-2 rule*

Aerobic-based exercises†
Exercises

Continuous cycling or intermittent sport-related activities (eg, repeated punches thrown and agility
ladder drills)

Equipment

Continuous: upright or recumbent cycle ergometer
Intermittent: punching bag/pad, gloves and agility ladder

Duration

≤20 min/session

Volume

Continuous: 5–10 min (weeks 1–8), 15 min (weeks 9–16), 20 min (weeks 17 onwards)
Intermittent: 3–5 bouts×30 s with 60 s recovery (weeks 1–4), 6–8 bouts×45 s with 60 s recovery (weeks
5–8), 8 bouts×60 s with 60 s recovery (weeks 9 onwards)

Intensity
Progression

~65%–80% of estimated MHR or RPE 4–6
Continuous: increases in resistance and pedalling speed
Intermittent: variations in activity profile and work-to-rest ratio (ie, from 1:2 to 1:1)

*Increasing weight when two additional repetitions on the last set of an exercise can be successfully completed for two consecutive
sessions.
†Aerobic-based exercise will be alternated from session to session, that is, either continuous cycling or intermittent sport-related activities
will be performed in a session.
MHR, maximum heart rate; NAT, neoadjuvant therapy; RM, repetition maximum; RPE, rating of perceived exertion (the 10-point Borg Scale).

will be alternated from session to session to provide greater
variety and training stimulus. Exercise intensity will be
manipulated from ~65% to 80% of estimated maximum
heart rate (MHR) (MHR=220-
age), corresponding to a
rating of perceived exertion (RPE) of 4–6 (Moderate to
Hard) on the 10-
point Borg Category-
ratio scale.35 For
continuous cycling, participants will be required to pedal
at a cadence of 50–80 rpm.36 The pedalling resistance and
speed will be progressed to elicit the target heart rate zone
or RPE. With regard to the intermittent component, 3–8
bouts of 30–60 s sport-related drills will be performed with
60 s rest intervals between adjacent bouts. A similar work-
to-rest ratio has been administrated in patients with cancer
undergoing chemotherapy.37
Controls
After completion of the baseline assessment and randomisation, the study investigator will advise the controls
to maintain their usual activities. No exercise prescriptions or recommendations will be provided to them. To
Luo H, et al. BMJ Open Gastro 2021;8:e000642. doi:10.1136/bmjgast-2021-000642

capture information concerning leisure-
time exercise
undertaken incidentally in the controls, a pre-established
physical activity log will be provided to them. In addition,
the study investigator will contact the controls via phone
once per month to facilitate data collection relating to
incidental exercise, potential adverse events (AEs) and
any changes in cancer treatment.
Treatment of exocrine pancreatic insufficiency
All study participants will be prescribed Creon (pancrelipase delayed-
release capsules) for the treatment of
potential exocrine pancreatic insufficiency.
DATA COLLECTION
Primary outcome
Feasibility metrics
1. Incidence and severity of AEs (defined as unfavourable responses to exercise and NAT undertaken as
part of the EXPAN trial but may not necessarily be
related to these treatments) will be tracked by the
5
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2.

3.

4.

5.

study investigator and participants, and identified
through review of medical records. Specifically, the
occurrence of AEs during and following an exercise session will be captured by the study investigator or participants using a pre-established tracking
log. Any NAT-related AEs will be actively monitored
by clinicians and obtained via medical records after
completion of the intervention. The severity of AEs
will be graded using the National Cancer Institute’s
Common Terminology Criteria for Adverse Events
(CTCAE, V.5.0).38
Eligibility rate will be calculated by dividing the number of eligible patients by the number of patients
screened; recruitment rate will be calculated by the
number of enrolled patients versus the number of eligible patients. We will assess eligibility and recruitment
rate at baseline. The number of excluded and unenrolled patients will be documented along with the relevant reasons by the study investigator.
Attrition rate will be determined by the number of
dropouts in each group versus the number originally
allocated and assessed prior to the potential alteration
of treatment and at completion of the exercise intervention. Reasons for dropping out will be documented
by the study investigator.
Attendance rate will be determined by the total and
weekly number of exercise sessions attended versus
the number of sessions prescribed (only for the intervention group). Reasons for non-attendance will be
documented by the study investigator.
Adherence rate will be determined by the number of
sessions where the prescribed resistance and aerobic-
based exercises are successfully completed (including
volume and intensity) versus the number of sessions
attended (only for the intervention group). A combination of exercise heart rate (tracked by Polar H10),
RPE (10-point Borg scale) and duration will be used
to monitor activity profile for aerobic-based exercises.
Adherence to resistance training will be assessed by
calculating the amount of exercise actually completed (ie, the number of exercises, sets, repetitions and
weights) and comparing to the individual prescribed
exercise in each session.39 Reasons for non-adherence
to an exercise prescription will be documented by the
study investigator.

Secondary outcomes
Patient-related and treatment-related endpoints
1. Rates of operability and R0 resection will be evaluated
in line with routine clinical examinations at the hospitals with the latest data collected prior to potential
alteration of treatment and at completion of the exercise intervention used for the EXPAN trial. Operability
rate refers to the proportion of participants who
achieve anatomical resectability status as defined by
the AGITG28 and proceed to PanCa surgery; R0 resection rate is defined as proportion of participants
who undergo tumour resection with a clear margin
6

2.

3.

4.

5.

6.

(>1 mm). The data will be extracted from participants’
medical records.
Progression-free survival (PFS) will be assessed in line
with routine clinical examinations at the hospitals with
the latest data collected prior to potential alteration of
treatment, at completion of the exercise intervention
and 6 months post the exercise intervention used for
the EXPAN trial. In this study, PFS is defined as the
length of time elapsed from the start of the exercise
intervention/postrandomisation to an indication of
disease progression or death from any cause. The data
will be obtained via participants’ medical records.
Chemotherapy RDI will be examined prior to potential alteration of treatment and at completion of the
exercise intervention. RDI is determined by the ratio
of actually delivered dose (mg/m2/week) against the
planned dose (mg/m2/week) of a regimen. For participants receiving a multiple-drug regimen, the RDI for
each drug and average RDI across all drugs included
in the regimen will be calculated. The data will be extracted from participants’ medical records along with
any documented reasons for regimen delay, change
and discontinuation.
Length of hospital stay (LOS) will be assessed in line
with routine clinical examinations at the hospitals in
participants who receive PanCa surgery. In this study,
LOS is defined as the duration of a single episode of
hospitalisation between the day completing surgical
resection and the day being discharged from the hospital. The data will be obtained through participants’
medical records at 6 months post the exercise intervention.
The incidence and severity of postsurgery complications will be assessed in line with routine clinical examinations at the hospitals in participants who undertake
PanCa surgery. We will use the Clavien-Dindo classification to define and grade the severity of surgical
complications.40 The data will be obtained via participants’ medical records at 6 months post the exercise
intervention.
Resumption of activities of daily living in participants
following surgical resection will be assessed at 3-month
and 6-month postexercise intervention using a self-
administrated questionnaire. The questionnaire is a
12-item Likert-scale used to rate the degree to which
the participants have resumed their usual activities of
daily living.41

Physical function
Physical function will be measured at baseline, prior to
potential alteration of treatment, and at completion of
the exercise intervention using a battery of standard tests
that are as follows:
1. One-repetition maximum (1RM) chest press and leg
press test is performed to assess muscle strength of
major muscle groups in the upper-body and lower-
body, respectively.42 The chest press test is conducted
on a Cybex chest press machine (Cybex International,
Luo H, et al. BMJ Open Gastro 2021;8:e000642. doi:10.1136/bmjgast-2021-000642
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Medway, Massachusetts, USA) and leg press on a
Cybex leg press machine. Following a general warm-
up, participants undertake two specific warm-up sets of
eight and three repetitions at approximately 50% and
70% of an estimated 1 RM, respectively. Subsequently,
single repetitions are performed with progressively
heavier weights until failure. The final weight lifted
successfully is recorded for analysis. To avoid unnecessary fatigue, three to five trials are attempted and a rest
interval of 1–2 min is given between trials.
2. Repeated chair rise test is used to evaluate lower-limb
muscle function.43 To perform the test, participants sit
on a hard-backed chair (seat height 43 cm from the
floor) with their arms folded across their chest. They
are instructed to rise as fast as possible to a full standing position and then return to a full sitting position
five times. Three trials are performed with a 1 min recovery between trials. The fastest time recorded will be
used in the analysis.
3. Four hundred metre walk test is administrated to
measure cardiorespiratory fitness and walking endurance.43 The test requires participants to walk 400 m
in a hallway back and forth on a 20 m course as fast as
possible. The time taken to complete the 400 m walk
will be used in the analysis.
4. Six-metre backwards tandem walk is undertaken to examine dynamic balance.44 Participants are required to
walk backwards in tandem stance (ie, placing one foot
directly behind the heel of the other with the shoes
touching) for a distance of 6 m. The time taken to
complete the distance is recorded for analysis.
Body composition and anthropometry
Whole body lean mass, fat mass and percentage body fat
will be assessed at baseline, prior to potential alteration
of treatment and at completion of the exercise intervention using dual-energy X-ray absorptiometry (DXA;
Horizon A, Hologic, Waltham, Massachusetts, USA).45 In
addition, body height and weight will be obtained using
a digital measuring station (SECA 763; seca gmbh & co.
kg., Hamburg, Germany) and waist and hip circumference using a constant tension tape measure.
Quality of life and psychological health
The European Organization for Research and Treatment
of Cancer (EORTC) Quality of Life Questionnaire Core
module (QLQ-C30)46 and the pancreatic cancer specific
module (QLQ-PAN26)47 will be used to assess QoL. To
assess cancer-related fatigue, the EORTC QLQ-C30 with
the addition of a validated 12-item fatigue module (QLQ-
FA12) by the EORTC48 will be administered. Psychological distress will be measured using the Brief Symptom
Inventory-18.49 These questionnaires will be completed
by participants at baseline, prior to potential alteration
of treatment and at completion of the exercise intervention. For participants who undergo PanCa surgery, they
will also complete these questionnaires at 3 months post
the exercise intervention.
Luo H, et al. BMJ Open Gastro 2021;8:e000642. doi:10.1136/bmjgast-2021-000642

Physical activity level
Self-reported physical activity level will be assessed using
the Godin-Shephard Leisure-Time Physical Activity Questionnaire50 at baseline, prior to potential alteration of
treatment and at completion of the exercise intervention. For participants who receive PanCa surgery, they
will also complete the questionnaire at 3 months post the
exercise intervention.
Enjoyment of sport-related activities
To explore participants’ views on intermittent sport-
related activities provided in the intervention, the intervention group will be asked to complete a modified
Physical Activity Enjoyment Scale (PACES)51 at completion of the exercise intervention.
Statistical analysis plans
Statistical analyses will be performed using SPSS 26.0
(IBM, Chicago, Illinois, USA) and R V.4.0.2 (https://
www.r-project.org/). Descriptive statistics will be used for
baseline demographic and clinical characteristics of each
group. Categorical variables will be presented as frequencies and proportions, and continuous variables will be
presented as means and SDs (or medians and IQR).
Between-
group differences in baseline characteristics
will be assessed using independent t-tests or the Mann-
Whitney U test, as appropriate, for continuous data and
the χ² test for categorical data.
The feasibility endpoints will be analysed descriptively
and reported as frequencies and/or proportions. The
differences between the intervention and control group
in changes over time for efficacy outcomes (excluding
LOS and PFS) will be assessed using linear mixed models
or generalised linear mixed models with a random-effect
factor for patients. Fixed-effect factors associated with
secondary outcomes of interest include intervention
assignment, time and an intervention by time interaction as well as actually completed dosage of the exercise
intervention and NAT. Analysis of LOS will be conducted
using zero-truncated negative binomial regression. With
regard to the analysis of PFS, the Kaplan-Meier method
with log-rank test will be used. The number of participants with disease progression within the study period
(ie, maximum 12 months) and the number of censored
patients will be presented. In addition, the Cox proportional hazards regression model will be used to estimate
the hazard ratio between the study arms. The intention-
to-treat principle will be applied to the efficacy outcomes
analysis. The use of radiotherapy and choice of chemotherapy drugs in participants will be adjusted as potential
confounding factors for the exercise intervention effects.
group differences will be reported using
All between-
the 95% CI. Further analysis of the association between
body composition and chemotherapy RDI at different
time points will be performed using linear regression or
generalised linear regression. Tests will be two-tailed and
p≤0.05 will be considered statistically significant.
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Monitoring
Monitoring of the EXPAN trial will be performed
through regular study progress reports review (6-month
to 12-month intervals) by the ECU Research Ethics Team
(RET) and the respective RET or Research Governance
Office (RGO) for SCGH and SJOGSH. This is in line with
the current Australian Code for the Responsible Conduct
of Research.52 The research team of the EXPAN trial is
also responsible for monitoring. A summary of exercise-
related AEs (if any) will be provided to the participants’
treating oncologists every 4 weeks. If there is any indication that the exercise intervention is causing harm, a
case-by-case analysis will be conducted by the research
team before stopping or modifying the intervention for a
participant. In addition, the research team will report to
the RETs and RGOs immediately in the event of a serious
AE (≥Grade 3 in the CTCAE).
ETHICS AND DISSEMINATION
Ethics approval
The research ethics of the EXPAN trial was reviewed
and approved by the respective Human Research Ethics
Committee at ECU (reference no.: 2020–02011-LUO) and
the participating hospitals in Perth, Australia, including
SCGH (reference no.: RGS 03956) and SJOGSH (reference no.: 1726). The trial was registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) on
20 October 2020 (ID: ACTRN12620001081909).
Protocol amendments
Any changes to the research protocol that may affect the
conduct of the EXPAN trial, and the safety and potential benefits of participants (such as study design, eligibility criteria, outcome measures and analysis methods)
require a substantive protocol amendment. Such amendment will be agreed on within the research team and
communicated timely to the involved RET/RGO through
their required review procedure, and approval will be
obtained before implementation. In addition, protocol
modifications will be tracked in the ANZCTR.
Confidentiality
On recruitment, each participant is assigned a unique
identification number. During the trial, individually
identifiable data/information will be deidentified with
the number immediately after collection. As required
by the ECU Data Management Plan, hard-copy records
(eg, paper-based questionnaires) will be kept in a separate lockable filing cabinet; digital data will be stored
on a password-protected computer and uploaded to a
SharePoint site that is exclusive to the EXPAN trial. All
the study data/information will only be accessible to the
study personnel. In accordance with the current Australian Code for the Responsible Conduct of Research,52
the data/information collected for the EXPAN trial will
be stored for at least 15 years following completion of
the study. After the minimum storage duration, all study
8

data/information will be permanently destroyed in an
appropriate way.
Dissemination plan
Research outcomes of the EXPAN trial will be presented
at national and international academic conferences and
submitted for publication in peer-reviewed journals. In addition, to facilitate participant retention in the trial, a summary
of individual results will be provided (on request) to those
who complete the study. The report will outline individual
results on body composition, muscle strength, functional
capacity, psychological health and QoL at each time point
and changes across all assessment time points.

DISCUSSION
The understanding of the role of exercise in patients
with PanCa and in particular for those during NAT is
limited due to their under representation in exercise
oncology research. To date, there are only seven individual published studies focusing exclusively on patients
with PanCa.22–24 Of them, only three studies (all without
control) have been conducted in patients during NAT
arm study,53 one case series25
(including one single-
26
and one case report. In addition, among the ongoing
exercise trials for patients with PanCa in ClinicalTrial.
gov, ANZCTR and CENTRAL, with the exception of
the EXPAN trial, there is only one RCT over the course
of preoperative therapy.54 In this context, additional
rigorous research is required to support the use of exercise in patients with PanCa undergoing NAT.
The EXPAN trial is designed to investigate primarily
the feasibility of a supervised, multicomponent exercise
medicine programme in patients with borderline resectable or locally advanced PanCa undergoing NAT. The
study will also provide indications of efficacy of the intervention on a wide range of clinical, physical and psychosocial endpoints. This is the first randomised controlled
exercise trial specifically for patients with PanCa in
Australia and is a collaborative research project between
EMRI-
ECU and high-
volume hospitals for PanCa in
Western Australia (ie, SCGH and SJOGSH).
The EXPAN intervention takes into account common
perceived barriers and facilitators to exercise in patients
with PanCa. Qualitative and quantitative research in this
patient group found that lack of motivation is among
barriers to exercise, while a supportive environment and
enjoyable activities may improve exercise uptake.55 56 To this
end, an exercise intervention containing sport-related activities may be a potential strategy for the patients providing
an interactive and enjoyable environment.57 As a result, a
multicomponent programme consisting of clinical-
based
resistance and aerobic exercises and adapted sport activities will be adopted given the promising results in patients
with PanCa undergoing NAT through a combined exercise
programme.24 An exercise intervention of this format has
recently been shown to be safe and effective in maintaining
Luo H, et al. BMJ Open Gastro 2021;8:e000642. doi:10.1136/bmjgast-2021-000642
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physical activity for patients with sedentary breast cancer
during adjuvant chemotherapy.58
Given the feasibility nature of the EXPAN trial, its results
will be used to determine whether a subsequent fully
powered RCT is needed. In addition, it will be an important
basis for research into whether exercise can be implemented
as a safe and efficacious component in a multidisciplinary
management strategy for patients with PanCa or peripancreatic malignancies treated with comparable procedures
(such as ampullary and periampullary).
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